Embracing Technology and Innovation “Key” to Easing Healthcare Crisis
09 Agosto 2022 - 7:30AM
Business Wire
Greater Toronto Area Company Improving
Healthcare Delivery and Treatments
Novo Integrated Sciences, Inc., a NASDAQ listed company
operating in the GTA (“Novo”), is pioneering the delivery of
non-catastrophic healthcare in both Canada and the U.S. through the
integration of medical technology, innovative diagnostic and
treatment solutions, rehabilitative sciences, and a game-changing
approach to eldercare, physiotherapy, virtual care, and homeopathic
treatment.
Novo is focused on safely shifting non-catastrophic healthcare
away from hospitals and into
doctors’ offices, clinics, and even patients’ homes. It’s a roadmap
to huge savings for government-run healthcare systems that are
collapsing under the strain of COVID-19’s lingering impacts.
Novo is using advances in medical technology and home
computers/smart phones to dramatically improve the ability for
patients to communicate with medical professionals and even get
assessments done quicker.
“We have incredibly powerful tools in our hands every day that
can allow us to not only communicate with our medical professionals
via video links, but our electronic devices can be used for
important but resource-consuming procedures like blood and saliva
tests for certain diseases and illnesses,” said Robert
Mattacchione, CEO of Novo Integrated Sciences Inc.
“The wait-times in hospitals have hit crisis levels. There is no
relief valve in sight that will ease the pressure, so we need to
focus on ways to shift care away from primary medical centres using
everyday technology and advancements in medical procedures,”
Mattacchione added.
Canada spent $308 Billion on healthcare in 2021, roughly $8,000
per person according to CIHI (Canadian Institute for Health
Information) research. Novo’s business model combines a number of
healthcare-related technologies, services, and products that make
access to quality care easier for families, with a new focus on a
breakthrough pure molecular water-based iodine spray for children,
IoNovo for Kids.
Health Canada recently granted IoNovo for Kids a Natural Product
Number (NPN). IoNovo for Kids is the first pure molecular
water-based iodine spray of its kind, dosed in a safe, ingestible
form for children, that is proven to be safe and effective, giving
families and doctors another tool to help keep families out of
hospitals. Doctors have prescribed iodine for decades as a means to
improve thyroid function, brain health, and improved immune system
function.
“You feel a tingle in your throat and you spray - it’s that
simple because the natural iodine elements in the spray erase the
viruses and bacteria that are present,” said Mattacchione.
Terence Mullins, iodine research specialist and President of
Terragenx, stated, “Back to school and back to work in September
will see fewer masks and therefore less protection against disease.
For decades, the world’s medical community has recognized iodine,
when safely ingested, as one of nature’s finest killers in the
microbial world. Here we have a safe, simple spray protecting
families from invisible dangers still wreaking havoc across the
globe. We use nature to combat nature’s own dangers. It’s a
powerful layer of protection for us all.”
About Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. is a Nasdaq listed U.S. company
(NASDAQ:NVOS) with subsidiaries and operations in both Canada and
the U.S. For more information, please visit
www.novointegrated.com
About Terragenx, Inc.
The IoNovo line of products are both Health Canada and FDA
approved for over the counter and e-commerce distribution. For more
information, please visit www.terragenx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220809005274/en/
Robert Mattacchione, CEO Novo Integrated Sciences, Inc.
robert.mattacchione@novointegrated.com (647) 829-7997
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024